IP Library › Granted Patent US 8,075,886
Granted Patent B2
US 8,075,886 · App. 12/493,871 · Granted Dec 13, 2011

Method of treatment using an anti-IL-B50 antibody

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,075,886
App. No.
12/493,871
Granted
Dec 13, 2011
Kind
B2
Abstract

Nucleic acids encoding mammalian cytokine receptor, e.g., for cytokine IL-B50, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.

Claims (7)

1. A method for treating allergic disease comprising administering to a patient in need thereof an antagonistic antibody or a fragment thereof that specifically binds to a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:6 in an amount sufficient to inhibit an activity selected from the group consisting of:

i. dendritic cell production of TARC, PARC or MDC; and

ii. up-regulation of a co-stimulatory or adhesion molecule on a dendritic cell, wherein said molecule is selected from the group consisting of HLA-DR, CD40, CD80, CD86, CD11a, CD18 and CD83,

wherein the allergic disease is thereby treated.

2. The method of claim 1 , wherein the activity that is inhibited is dendritic cell production of TARC, PARC or MDC.

3. The method of claim 1 , wherein the activity that is inhibited is up-regulation of HLA-DR, CD40, CD80, CD86, CD11a, CD18 and CD83.

4. The method of claim 1 , wherein the activity that is inhibited is up-regulation of HLA-DR, CD40 and CD80.

Assignments (1)
CHANGE OF NAME Recorded Aug 30, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028884/0151 →